country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-W338819

Copy Link Print Information

Clobetasol

Customer Review

Based on 1 Customer Validation

Clobetasol is a glucocorticoid and Smoothened agonist that can cross the blood-brain barrier. Clobetasol induces Smo-dependent activation of the Shh signaling pathway and nuclear translocation of Gli1. Clobetasol promotes remyelination and reduces myelin loss in lesions of neuromyelitis optica (NMO). Clobetasol may cause adrenal suppression, cushingoid appearance, and local adverse reactions including dysgeusia, xerostomia, and gastroesophageal burning. Clobetasol can be used in research related to neurodegenerative diseases, oral lichen planus, mucous membrane pemphigoid, and neuromyelitis optica.

For research use only. We do not sell to patients.

CAS No.: 25122-41-2
Formula: C₂₂H₂₈ClFO₄
Molecular Weight:410.91

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Clobetasol Chemical Structure

CAS No.: 25122-41-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	0.007 μM Compound: Clobetasol	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	[PMID: 23411072]
PBMC	IC₅₀	0.07 nM Compound: Clobetasol	Inhibition of PHA-induced IL4 release in human PBMC cells Inhibition of PHA-induced IL4 release in human PBMC cells	[PMID: 32631518]
PBMC	IC₅₀	0.14 nM Compound: Clobetasol	Inhibition of LPS-induced IL12p40 release in human PBMC cells Inhibition of LPS-induced IL12p40 release in human PBMC cells	[PMID: 32631518]
PBMC	IC₅₀	0.16 nM Compound: Clobetasol	Inhibition of PHA-induced IFNgamma release in human PBMC cells Inhibition of PHA-induced IFNgamma release in human PBMC cells	[PMID: 32631518]
PBMC	IC₅₀	0.23 nM Compound: Clobetasol	Inhibition of LPS-induced TNFalpha release in human PBMC cells Inhibition of LPS-induced TNFalpha release in human PBMC cells	[PMID: 32631518]
PBMC	IC₅₀	4.2 μM Compound: Clobetasol	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL6 release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL6 release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	[PMID: 23411072]
PBMC	IC₅₀	4.4 μM Compound: Clobetasol	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	[PMID: 23411072]

In Vitro

Clobetasol (0.1-25 µM) enhances the metabolic turnover of neural stem cells (NSCs) derived from the subventricular zone (SVZ) of mice via a Smo-dependent signaling pathway^[1].
Clobetasol (5 µM) doubles the cell growth rate of neural stem cells (NSCs) derived from the subventricular zone (SVZ) of mice via the Smo-dependent signaling pathway^[1].
Clobetasol increases Gli1 mRNA levels in mouse SVZ-derived neural stem cells (NSCs) via the Smo-dependent signaling pathway^[1].
Clobetasol (0.3-10 μM; 6 days) promotes the maturation of primary mouse oligodendrocyte precursor cells, and approximately 15% of the cells become MBP-positive after incubation at 5 μM for 6 days^[3].
Clobetasol (6 days) promotes remyelination and increases the number of mature oligodendrocytes in cultured mouse cerebellar slices with demyelination induced by AQP4-IgG and complement after 6 days of treatment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

mouse subventricular zone (SVZ)-derived neural stem cells (NSCs)
Concentration:

0.1 µM, 1 µM, 5 µM, 25 µM; 5 µM plus 1 µM cyclopamine
Incubation Time:

Not specified
Result:

Increased NSC MTT turnover to 152.1% of control levels at 5 µM, with a p-value < 0.0001.
Caused a dose-dependent reduction in MTT turnover at 0.1, 1, 25 µM.
Reversed the increased MTT turnover induced by 5 µM clobetasol when co-treated with 1 µM cyclopamine.

In Vivo

Clobetasol (2 mg/kg/day; intraperitoneal injection; days 5 to 8) reduces myelin loss by approximately 60% and increases the number of mature oligodendrocytes in a mouse model of neuromyelitis optica^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD1 (male, wild-type, 10-12 weeks of age, intracerebral stereotaxic infusion of AQP4-IgG and human complement)^[3]
Dosage:

2 mg/kg/day
Administration:

i.p.; daily; 8 days (day 1 to day 9); daily; 5 days (day 4 to day 9)
Result:

Reduced myelin loss by ~60% compared to vehicle-treated mice.
Increased the number of mature CC1-positive oligodendrocytes in and around lesions significantly compared to vehicle-treated mice.
Did not significantly alter initial astrocyte damage (AQP4 loss), inflammation (Iba1 and CD45 immunofluorescence), or complement activation (C5b-9 deposition) compared to vehicle.
Produced significantly greater remyelination than vehicle when administered starting on day 4 (post-demyelination).

Chemical Information

CAS No. 25122-41-2
Appearance Solid
Molecular Weight 410.91
Formula C₂₂H₂₈ClFO₄
SMILES

F[C@@]12[C@](CCC([C@@]2(C=C3)C)=CC3=O)([H])[C@@]4([H])[C@](C[C@@H]1O)([C@](O)([C@H](C4)C)C(CCl)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Vicario N, et al. Clobetasol Modulates Adult Neural Stem Cell Growth via Canonical Hedgehog Pathway Activation. International journal of molecular sciences. 2019 Apr 23;20(8):1991. [Content Brief]

[2]. Varoni EM, et al. Pharmacokinetics study about topical clobetasol on oral mucosa. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2012 Mar;41(3):255-60. [Content Brief]

[3]. Yao X, et al. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta neuropathologica communications. 2016 Apr 26;4(1):42. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote